Significance of human epidermal growth factor receptor 2 expression in colorectal cancer

Tu,Jinhua; Yu,Yinghao; Liu,Wei; Chen,Shunping

doi:10.3892/etm.2014.2063

Significance of human epidermal growth factor receptor 2 expression in colorectal cancer

Authors:
- Jinhua Tu
- Yinghao Yu
- Wei Liu
- Shunping Chen
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou, Fujian 350025, P.R. China
Published online on: November 11, 2014 https://doi.org/10.3892/etm.2014.2063
Pages: 17-24

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the protein expression level of human epidermal growth factor receptor 2 (HER‑2) using immunohistochemistry (IHC), and assess the association with clinicopathological parameters and the prognosis of patients with colorectal cancer (CRC). In addition, the current study observed the consistency between the levels of HER‑2 protein expression determined by IHC and HER‑2 gene amplification determined by fluorescence in situ hybridization (FISH) in the CRC samples. Overexpression of HER‑2 and gene amplification were examined with semiquantitative standardized IHC in 878 formalin‑fixed paraffin‑embedded CRC samples, while 102 of these cases were analyzed with FISH. A total of 102 cases (11.6%), out of the 878 cases, were determined by IHC to overexpress HER‑2. Of these, 25 cases were strongly positive (IHC3+), while 77 cases revealed moderate staining (IHC2+). HER‑2 overexpression was more frequent in early‑stage cases compared with advanced‑stage cases of CRC (P<0.001). However, there was no association observed between HER‑2 overexpression and clinicopathological parameters. FISH analysis revealed that 64% (16/25) of the IHC3+ cases had HER‑2 gene amplification. By contrast, only 6.5% (5/77) of the IHC2+ cases, and none of the 20 randomly selected IHC0 or 1+ cases, demonstrated HER‑2 gene amplification. Furthermore, no associations were observed between HER‑2 overexpression or gene amplification with the survival time. Thus, the present study observed that HER‑2 overexpression does not correlate with other clinicopathological data or the survival rate, with the exception of clinical stages. However, IHC3+ and 2+ cases should be further analyzed by FISH to assess the status of the HER‑2 gene in CRC. Patients with HER‑2 gene amplification may constitute as potential candidates for targeted therapy with trastuzumab.

View Figures

View References

1	Ferlay J, Shin H, Bray F, et al: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. [Internet]. International Agency for Research on Cancer; Lyon, France: 2010, http://globocan.iarc.fruri. Accessed October 7, 2012
2	Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signalling network: receptor heterodimerisation in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
3	Smith I, Procter M, Dowsett M, et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
4	Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
5	Bernhard H1, Salazar L, Schiffman K, et al: Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer. 9:33–44. 2002. View Article : Google Scholar : PubMed/NCBI
6	Chen J, Li DS, Yu YH, et al: Clinical significance of Her-2 protein expression in gastric cancer. Shi Jie Hua Ren Xiao Hua Za Zhi. 18:1375–1379. 2010.(In Chinese).
7	Ford R, Schwartz L, Dancey J, et al: Lessons learned from independent central review. Eur J Cancer. 45:268–274. 2009. View Article : Google Scholar
8	Takahari D, Yamada Y, Okita NT, et al: Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology. 76:42–48. 2009. View Article : Google Scholar
9	Lim SW, Kim HR, Kim HY, et al: Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol (Dordr). 36:311–321. 2013. View Article : Google Scholar
10	Park DI, Kang MS, Oh SJ, et al: HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 22:491–497. 2007. View Article : Google Scholar
11	Demirbaş S, Sücüllü I, Yildirim S and Celenk T: Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer. Turk J Gastroentrol. 17:13–19. 2006.
12	Kavanagh DO, Chambers G, O’Grady L, et al: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 9:12009. View Article : Google Scholar : PubMed/NCBI
13	Ismail HM, El-Baradie M, Moneer M, et al: Clinico-pathological and prognostic significance of p53, Bcl-2 and Her-2/neu protein markers in colorectal cancer using tissue microarray. J Egypt Natl Canc Inst. 19:3–14. 2007.
14	Rossi HA, Liu Q, Banner B, et al: The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J. 8:268–275. 2002. View Article : Google Scholar : PubMed/NCBI
15	Essapen S, Thomas H, Green M, et al: The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 24:241–248. 2004.PubMed/NCBI
16	Antonacopoulou AG, Tsamandas AC, Petsas T, et al: EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology. 53:698–706. 2008. View Article : Google Scholar : PubMed/NCBI
17	Ramanathan RK, Hwang JJ, Zamboni WC, et al: Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22:858–865. 2004. View Article : Google Scholar
18	Kapitanović S, Radosević S, Kapitanović M, et al: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 112:1103–1013. 1997. View Article : Google Scholar
19	Half E, Broaddus R, Danenberg KD, et al: HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 108:540–548. 2004. View Article : Google Scholar
20	Kruszewski WJ, Rzepko R, Ciesielski M, et al: Expression of HER-2 in colorectal cancer does not correlate with prognosis. Dis Markers. 29:207–212. 2010. View Article : Google Scholar
21	Kountourakis P, Pavlakis K, Psyrri A, et al: Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 12:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
22	Schuell B, Gruenberger T, Scheithauer W, et al: HER 2/neu protein expression in colorectal cancer. BMC Cancer. 6:1232006. View Article : Google Scholar : PubMed/NCBI
23	Kim JY, Lim SJ and Park K: Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarray. Appl Immunohistochem Mol Morphol. 12:67–70. 2004. View Article : Google Scholar : PubMed/NCBI
24	Marx AH, Burandt EC, Choschzick M, et al: Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol. 41:1577–1585. 2010. View Article : Google Scholar : PubMed/NCBI
25	Herreros-Villanueva M, Rodrigo M, Claver M, et al: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep. 38:1315–1320. 2011. View Article : Google Scholar
26	Pappas A, Lagoudianakis E, Seretis C, et al: Clinical role of HER-2/neu expression in colorectal cancer. J BUON. 18:98–104. 2013.PubMed/NCBI
27	Li Q, Wang D, Li J and Chen P: Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 11:2772011. View Article : Google Scholar : PubMed/NCBI
28	Seo AN, Kwak Y, Kim DW, et al: HER2 Status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 9:e985282014. View Article : Google Scholar : PubMed/NCBI
29	Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
30	Hamtilon SR and Aaltonen LA: World Health Organization classification of tumours. Tumours of the oesophagus. Pathology and genetics tumors of the digestive system. IARC Press; Lyon: 2006
31	Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
32	Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 18:3651–3664. 2000.PubMed/NCBI
33	Tavangar SM, Shariftabrizi A and Soroush AR: Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients. Med Sci Monit. 11:CR123–CR126. 2005.PubMed/NCBI
34	McKay JA, Loane JF, Ross VG, et al: c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 86:568–573. 2002. View Article : Google Scholar : PubMed/NCBI
35	Mann M, Sheng H, Shao J, et al: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 120:1713–1719. 2001. View Article : Google Scholar : PubMed/NCBI
36	Pohl M, Stricker I, Schoeneck A, et al: Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol. 135:1377–1386. 2009. View Article : Google Scholar : PubMed/NCBI
37	Liu W, Zhong S, Chen J and Yu Y: HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 46:e31–e37. 2012. View Article : Google Scholar
38	Rossi E, Ubiali A, Cadei M, et al: HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl Immunohistochem Mol Morphol. 14:127–131. 2006. View Article : Google Scholar : PubMed/NCBI
39	Chibon F, de Mascarel I, Sierankowski G, et al: Prediction of HER2 gene status in HER2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol. 22:403–409. 2009. View Article : Google Scholar
40	Bartlett JM, Going JJ, Mallon EA, et al: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 195:422–428. 2001. View Article : Google Scholar : PubMed/NCBI
41	Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 29:1221–1227. 2005. View Article : Google Scholar : PubMed/NCBI
42	Dal Lago L, Durbecq V, Desmedt C, et al: Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 5:2572–2579. 2006. View Article : Google Scholar : PubMed/NCBI
43	Winston JS, Ramanaryanan J and Levine E: HER-2/neu evaluation in breast cancer are we there yet? Am J Clin Pathol. 121(Suppl): S33–S49. 2004.PubMed/NCBI
44	Seidal T, Balaton AJ and Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol. 25:1204–1207. 2001. View Article : Google Scholar : PubMed/NCBI
45	Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634. 2008. View Article : Google Scholar : PubMed/NCBI
46	Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
47	Liu W, Wang L, Yu YH, et al: Detection of k-ras gene mutations in Chinese patients with colorectal cancer. World Chinese Journal of Digestology. 19:1367–1374. 2011.
48	LaBonte MJ, Wilson PM, Fazzone W, et al: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 71:3635–3648. 2011. View Article : Google Scholar : PubMed/NCBI
49	Chen J, Li Q, Wang C, Wu J and Zhao G: Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol. 17:1555–1563. 2010. View Article : Google Scholar : PubMed/NCBI